Follow Us On

Facebook  Linkedin  X  


2025 Medicare Fee Schedule Targets Telehealth

Fortunately, Congress is progressing with a bill to reduce the impact of cuts and address telehealth issues



Ever since the COVID-19 public health emergency (PHE) was declared in 2020, telehealth billing rules have changed repeatedly, making it difficult to keep up. While many telehealth flexibilities are still in place, some will be going away effective January 1, 2025.


That’s the word from the 2025 Medicare Physician Fee Schedule Final Rule, which CMS released on November 1. The big news in the Final Rule was that the conversion factor – which Part B Medicare administrative contractors use to calculate reimbursement – was cut by 2.8%, which will impact physicians’ bottom lines significantly in the new year if Congress doesn’t step in and raise that rate.


Primary care physicians may be particularly interested in how the Final Rule will impact telehealth.


Read More

Registration is open for

ASIPP's 2025 Annual Meeting

We would love it if you would register and join us in Orlando!

Attendee Registration
Exhibitor Registration
Hotel Reservations
Exhibitor Prospectus





What Will Be the Next Ozempic?






More than 1 in 8 Americans have taken Ozempic, the popular diabetes and weight loss drug. That makes it one of the most popular medications in history just seven years after hitting the market, with Ozempic and similar drugs the most popular class of medications by overall spending in the U.S. in 2023. 


This surge in popularity has been relatively sudden, with the pandemic and celebrity influencers playing no small part in its marketing. In 2021, Ozempic wasn’t even on the top 20 list of best-selling drugs worldwide. 


But by 2023, Ozempic reached third place on that list. And late last year, Nature forecast Ozempic would be the second most profitable drug in the world in 2024 with sales over $16 billion.


Read More

Mark Your Calendar for These

Upcoming ASIPP Webinars!

Our Sponsor




Anthem Blue Cross Blue Shield calls off surgery anesthesia cap




A major health insurance company is backing off of a controversial plan to limit coverage of anesthesia, according to public officials.


Why it matters: Anthem Blue Cross Blue Shield recently decided to "no longer pay for anesthesia care if the surgery or procedure goes beyond an arbitrary time limit, regardless of how long the surgical procedure takes," according to the American Society of Anesthesiologists, which opposed the decision.


  • The decision covered plans in Connecticut, New York and Missouri.
  • The insurer had based the move on surgery time metrics from the Centers for Medicare and Medicaid Services, NPR reported.


Read More

FREE REGISTRATION UNTIL DECEMBER 16!


Join CALSIPP before December 16 and attend the

2025 CALSIPP Annual Meeting for FREE!


Don’t miss this opportunity to connect with leaders in interventional pain,

learn cutting-edge techniques, and elevate your practice. 

Join CALSIPP
Register Today



‘Tough love’: How RFK Jr.’s views on addiction could bring a new era of U.S. drug policy 




Despite the seemingly uncontroversial goal of Robert F. Kennedy Jr. to “Make America Healthy Again,” many of his health care stances are deeply divisive: In the last two years alone, he has suggested that Covid-19 was genetically engineered to spare specific ethnicities, stated that radiation from cell phones causes cancer, and doubled down on the long-disproven claim that HIV does not cause AIDS. 


But at least one health care cause that has occupied much of his attention in 2024, in contrast, has major unifying potential: the addiction and opioid crisis. As a presidential candidate, Kennedy cast the issue as a symbol of the nation’s broader ills. He traveled the country with a film crew to make a documentary focused on addiction, sharing his own struggles with heroin and alcohol. He surrounded himself with doctors, recovery advocates, judges, and public health officials, seeking an answer to a question that has evaded three successive presidents: how can the U.S. bring its decades-long drug crisis to an end? 


According to a STAT examination of Kennedy’s past statements on drug use and his own recovery, his documentary, and interviews with multiple advocates he spent time with during filming, his philosophy toward addiction policy is ideologically flexible. Kennedy has pitched a nationwide system of “healing farms,” espoused the virtues of 12-step recovery like Alcoholics Anonymous, and advocated “tough love” for people battling addiction. He also repeatedly expressed his admiration for Amsterdam’s response to its own drug epidemic decades ago, which included providing prescription heroin to drug users not ready to stop, and suggested at one point he was open to the controversial practice of supervised consumption. His biggest apparent takeaway was simple: What America is doing hasn’t worked. 


Read More


New 2025 Dates

Mark your calendars!




January 25, February 15,

March 1, and March 29


  • ABIPP Part I

Four (4) hour virtual exam


  • ABIPP Path – Combined CCPM/ CSM Exam

For those with subspecialty in Pain Medicine

Two (2) hour virtual exam


  • ABIPP Competency Exam in IPM

For those without primary board certification

Two (2) hour virtual exam


  • ABIPP Competency Exam in Regenerative Medicine

Two (2) hour virtual exam


  • Controlled Substance Management Competency Exam

Two (2) hour virtual exam


  • Documentation, Coding, Compliance, Practice Management Competency Exam

Two (2) hour virtual exam

Exam Dates

 


Spending less, living longer: What the U.S. can learn from Portugal’s innovative health system




Getting to the MRI machine at one of this city’s largest public hospitals means taking a trip through time. Plastic waiting room chairs in radiology sit amid centuries-old blue and white Azulejo tiles, while a nearby chapel glimmers with Renaissance statuary and paintings. Hospital de São José’s ambulance bays, exam rooms, and labs, after all, occupy a former college the Jesuits started building in 1579.


This recycling of a timeworn campus that somehow survived Lisbon’s devastating 1755 earthquake exemplifies Portugal’s health system: Instead of spending money on gleaming new hospitals and expensive drug therapies, the country focuses on old-fashioned primary care and public health.


It’s a strategy that has served Portugal well, and one that health care experts point to as a model the United States might learn from as it confronts soaring medical costs and, by many measures, deteriorating health. 


Read More

Abstract submissions are open for

ASIPP's 2025 Annual Meeting!


The abstract submission deadline is March 10, 2025. 


Don't miss this opportunity to share your insights

and help shape the future of pain management.

Abstract Guidelines
Submit Abstract

What Happened to the Canadian Teen Who Became Critically Ill With H5N1 Bird Flu?

Public health investigation is closed, but officials haven't provided patient updates



Canadian public health officials closed their investigation into the teenager who became critically ill with the H5N1 bird flu virus, with no source of infection identified.


It's not clear whether the teenager recovered or was released from the hospital. Andy Watson, director of communications for the Office of the Provincial Health Officer in British Columbia, said in an email to MedPage Today that the office does not provide patient status updates due to privacy.


The office "won't be providing any updates on the status of the teenaged patient or this now complete investigation unless there is a need from a public health perspective to do so," Watson said in the email.


Read More

- ASIPP Members Only Site Information -
  1. To log in for the first time you will need to click “forgot password” at the bottom of the login window.
  2. Check your email and then log in as directed.
  3. If you have problems logging into your account, click here.




Your Guide to COVID Vaccines for 2024-2025





The updated COVID vaccines for 2024-2025 are officially here, designed to target the latest variants and offer robust protection — but getting Americans to roll up their sleeves could prove harder than ever. With COVID cases on the decline, many people feel the urgency has passed.


As of Dec. 2, the CDC reports that COVID test positivity remains low, rising slightly to 4.5% for the week ending Nov. 23 compared to 4.2% the previous week. That’s a far cry from the early days of 2022, when positivity rates soared above 30%. Emergency room visits for COVID now make up just 0.5%, and deaths are down to 0.8% of total weekly fatalities, compared to 1% the previous week.


This steady improvement in the numbers may explain why a recent Pew Research Center survey revealed that 6 in 10 US adults have no plans to get the updated vaccine this year.


Read More

 

AGENDA

 COMING SOON!

REGISTRATION

COMING SOON!

Hotel Reservations
Prospectus






Malpractice in the Age of AI






Instead of sitting behind a laptop during patient visits, the pediatrician directly faces the patient and parent, relying on an ambient artificial intelligence (AI) scribe to capture the conversation for the electronic health record (EHR). A geriatrician doing rounds at the senior living facility plugs each patient’s medications into an AI tool, checking for drug interactions. And a busy hospital radiology department runs all its emergency head CTs through an AI algorithm, triaging potential stroke patients to ensure they receive the highest priority. None of these physicians have been sued for malpractice for AI usage, but they wonder if they’re at risk.


In a recent Medscape report, AI Adoption in Healthcare, 224 physicians responded to the statement: “I want to do more with AI but I worry about malpractice risk if I move too fast.” Seventeen percent said that they strongly agreed while 23% said they agreed — a full 40% were concerned about using the technology for legal reasons. 


Malpractice and AI are on many minds in healthcare, especially in large health systems, Deepika Srivastava, chief operating officer at The Doctors Company, told Medscape Medical News. “AI is at the forefront of the conversation, and they’re [large health systems] raising questions. Larger systems want to protect themselves,” Srivastava said. 


Read More

The updated Evidence-Based Clinical Guidelines for the Use of Implantable Peripheral Nerve Stimulation in the Treatment of Chronic Pain from ASIPP are now available! This 92-page publication includes 374 references, 20 tables (plus 8 appendix tables), and 9 figures.


These guidelines support the use of implantable peripheral nerve stimulation leads and neurostimulators in patients with moderate to severe chronic pain refractory to two or more conservative treatments, aim to optimize patient outcome, and promote health equity through the integration of PNS technology in clinical practice.


Click here to read the special issue!

Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.


Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.


Interested in becoming a member of the PMCR Editorial Board?

Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.


For more information or to submit your articles, click here.

 

CASE REPORT

Tibial Nerve Mononeuropathy Post-COVID-19 and Successful Management with Peripheral Nerve Stimulation: A Case Report


Luis Miguel Escano Volquez, MD, Sri Harsha Kanuri, MD, and Roger Haddad, DO




Abstract


BACKGROUND: Infection with COVID-19 has evolved from a novel health crisis into an entity with a myriad of increasingly recognized sequelae. Among these, peripheral neuropathy is often an underrecognized and underdiagnosed complication. Neuropathic pain can be challenging to treat with many cases being refractory to conservative management, often requiring advanced techniques. Neuromodulation has become an important tool for the treatment of the refractory cases.


CASE REPORT: We present a case of a 43-year-old woman with refractory right tibial mononeuropathy secondary to COVID-19 infection who was treated successfully using peripheral nerve stimulation.


CONCLUSIONS: The use of peripheral neuromodulation represents a pivotal strategy for the management of difficult cases. Our case highlights the first use of neuromodulation to treat neuropathic pain secondary to COVID-19 infection. We hope that this case sparks further research on the topic, which could lead to better clarification of this condition and potential expansion of treatment strategies.


KEY WORDS: Neuromodulation, peripheral nerve stimulator, long COVID, tibial neuropathy, neuropathic pain


Read More

New Issue Now Available!

 

HEALTH POLICY RESEARCH

Exponential Decline of 28.9% in Utilization of Interventional Pain Management Techniques Among Medicare Beneficiaries From 2019 to 2022: Updated Analysis on the Ongoing Effects of COVID-19, Economic Decline, the Affordable Care Act (ACA), and Medical Poli


Laxmaiah Manchikanti, MD, Vidyasagar Pampati, MSc, Mahendra R. Sanapati, MD, Devi E. Nampiaparampil, MD, Nebojsa Nick Knezevic, MD, PhD, Alan D. Kaye, MD, PhD, Amol Soin, MD, Christopher G. Gharibo, MD, Alaa Abd-Elsayed, MD, and Joshua A. Hirsch, MD




Abstract


BACKGROUND: Numerous studies have highlighted the escalating costs associated with managing low back and neck pain, as well as other musculoskeletal disorders. In the past, there was a notable increase in the use of interventional techniques to address these disorders. However, the COVID-19 pandemic disrupted various chronic pain treatment approaches, including interventional procedures and opioid use, following a broader trend of reduced healthcare services. Consequently, there was an 18.7% decline in the use of interventional techniques per 100,000 Medicare beneficiaries between 2019 and 2020, a stark contrast to the previous growth patterns, despite some initial declines observed starting in 2017.


OBJECTIVES: This analysis aims to provide an updated evaluation of the utilization of interventional techniques for chronic pain management in the U.S. Medicare population.


STUDY DESIGN: A retrospective cohort study examining utilization patterns and factors affecting interventional techniques for chronic pain management in the FFS Medicare population in the United States from 2000 to 2022.


METHODS: Data for this analysis was obtained from the Centers for Medicare & Medicaid Services (CMS) master database, specifically the physician/supplier procedure summary, spanning the years 2000 to 2022.


RESULTS: This retrospective cohort study found that the rate of interventional pain management services per 100,000 Medicare beneficiaries showed a cumulative decline between 2019 and 2022 of 28.9%, with an annual decrease of 10.7%. This contrasts sharply with the 2010-2019 period, which saw a small annual decline of 0.4%. Particularly significant was the sharp reduction of 18.7% from 2019 to 2020, coinciding with the pandemic. From 2020 to 2021, the decline slowed to 1.1%, before accelerating again with an 11.5% drop between 2021 and 2022. 


LIMITATIONS: Data were available only through 2022 and were limited to the FFS Medicare population; utilization patterns for Medicare Advantage Plans, which accounted for nearly 50% of Medicare enrollment in 2022, were not included. Additionally, this analysis shares the inherent limitations of all retrospective reviews based on claims data.


CONCLUSION: This retrospective analysis demonstrates a significant reduction in the use of interventional pain management techniques from 2019 to 2022. Contributing factors to this decline likely include the lasting effects of COVID-19, economic challenges, the Affordable Care Act (ACA), and evolving local coverage determination policies.


KEY WORDS: Interventional pain management, chronic spinal pain, interventional techniques, epidural injections, adhesiolysis, facet joint interventions, sacroiliac joint injections, disc procedures, other types of nerve blocks, economic decline, Affordable Care Act (ACA)


Read More

SYSTEMATIC REVIEW

Mindfulness Meditation for Fibromyalgia Syndrome: A Systematic Review and Meta-analysis


Shuo Meng, MM, Chunfeng Cao, MM, Minghua Zhang, MM, Jing Dong, PhD, and Minpeng Lu, PhD




Abstract


BACKGROUND: The effectiveness of mindfulness meditation (MM) for the treatment of fibromyalgia syndrome (FMS) is unknown and needs to be updated.


OBJECTIVE: This study aimed at investigating the effectiveness of MM for the treatment of FMS.


STUDY DESIGN: A systematic review and meta-analysis.


METHODS: A comprehensive search of relevant studies published from the databases’ inception through April 12, 2023 was conducted within the following databases: Cochrane Library, Embase, MEDLINE, PubMed, Clinicaltrials.gov, and PsycINFO. We included randomized controlled trials that reported at least one of the following outcome indicators: the Fibromyalgia Impact Questionnaire (FIQ), the Pittsburg Sleep Quality Index (PSQI), the Beck Depression Inventory (BDI), and the Perceived Stress Scale (PSS). Results are presented in terms of mean difference (MD), supplemented by 95% CIs The I2 statistic assessed heterogeneity across 3 distinct observational time frames. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework to appraise the robustness of the evidence.


RESULTS: Ten randomized controlled trials were selected from 1,377 citations (n = 818). Various MM regimens were reported (type of mindfulness, duration, schemes, and ingredients). Among 818 patients, very low to moderate evidence indicated that MM could reduce FIQ in the short-term (MD = -6.20; 95% CI,-8.51 to -3.89; P < 0.05; GRADE: moderate); a lower PSQI score (MD = -1.84; 95% CI, -3.35 to -0.33; P < 0.05; GRADE: very low); a reduce BDI score (MD = -3.26; 95% CI, -5.77 to -0.76; P < 0.05; GRADE: moderate); and a decreased PSS score (MD = -4.85; 95% CI, -8.22 to -1.49; P < 0.05; GRADE: very low). At medium-term follow-up, MM consistently reduced the BDI score (MD = -2.88; 95% CI, -4.98 to -0.79; P < 0.05; GRADE: moderate) and decreased the PSS score (MD = -2.76; 95% CI, -4.82 to -0.70; P < 0.05; GRADE: moderate) but there was no significant difference in FIQ scores (MD = -2.78; 95% CI, -6.32 to 0.76; P > 0.05; GRADE: low) and PSQI scores (MD = -1.28; 95% CI, -3.35 to -0.80; P > 0.05; GRADE: very low). However, at long-term follow-up, MM still reduced FIQ scores (MD = -6.09; 95% CI, -9.01 to -3.16; P < 0.05; GRADE: moderate).


LIMITATIONS: The relatively small sample size and the average quality of the included studies may have introduced biases. The time and method of meditation in the included studies were not completely unified, and there were confounding factors. Additionally, the limited amount of available literature is a challenge. Despite focusing on randomized controlled trials, there is heterogeneity among these studies. Future research should aim for larger, higher-quality studies to address these limitations and provide a more comprehensive understanding of MM’s effectiveness in fibromyalgia management.


CONCLUSIONS: Very low to moderate evidence shows that MM improves quality of life, relieves stress, and relieves insomnia and depression in patients with FMS in the short-term. Notably, the improvement in depression and stress levels continued into the medium-term period. Furthermore, quality of life improvement was discernible at long-term follow-up. This suggests that MM can be used as an adjunct therapy for FMS.


International Prospective Register of Systematic Reviews (PROSPERO) Registration Number: CRD42023442356


KEY WORDS: Fibromyalgia, fibromyalgia syndrome, mindfulness meditation, meta-analysis, systematic review, musculoskeletal disease


Read More

 




ASIPP is now in collaboration with Curi Medical Liability Program





Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices. 

 

Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.

 

Group Purchasing Organization Offer Better Pricing and Creates Added Value


ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.



Learn More

 

ASIPP, Fedora Healthcare Solutions Partnership


ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.


We have received a tremendous amount of interest in the ASIPP billing and coding program.


Click here to learn more about the negotiated rate for practices and more!

Like and follow ASIPP® on Facebook, X, and LinkedIn for the most

up-to-date news related to you, your practice, and your patients!